Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Nat Med

Retrieve available abstracts of 105 articles:
HTML format

Single Articles

    July 2021
  1. MACHINGAIDZE S, Wiysonge CS
    Understanding COVID-19 vaccine hesitancy.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.

  2. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
    COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
    PubMed     Abstract available

  3. O'LEARY K
    Another COVID-19 vaccine to boost rollout.
    Nat Med. 2021 Jul 15. pii: 10.1038/d41591-021-00045.

  4. BARROS-MARTINS J, Hammerschmidt SI, Cossmann A, Odak I, et al
    Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Nat Med. 2021 Jul 14. pii: 10.1038/s41591-021-01449.
    PubMed     Abstract available

  5. LOUBET P, Wittkop L, Tartour E, Parfait B, et al
    A French cohort for assessing COVID-19 vaccine responses in specific populations.
    Nat Med. 2021 Jul 12. pii: 10.1038/s41591-021-01435.

  6. CHEMAITELLY H, Yassine HM, Benslimane FM, Al Khatib HA, et al
    mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Nat Med. 2021 Jul 9. pii: 10.1038/s41591-021-01446.
    PubMed     Abstract available

    A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
    Nat Med. 2021 Jul 8. pii: 10.1038/s41591-021-01432.

  8. COWLING BJ, Lim WW, Cobey S
    Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01440.

    June 2021
  9. O'LEARY K
    Building a pandemic-proof vaccine.
    Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.

  10. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    PubMed     Abstract available

  11. KUSTIN T, Harel N, Finkel U, Perchik S, et al
    Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Nat Med. 2021 Jun 14. pii: 10.1038/s41591-021-01413.
    PubMed     Abstract available

  12. MILMAN O, Yelin I, Aharony N, Katz R, et al
    Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
    Nat Med. 2021 Jun 10. pii: 10.1038/s41591-021-01407.
    PubMed     Abstract available

  13. PRITCHARD E, Matthews PC, Stoesser N, Eyre DW, et al
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01410.
    PubMed     Abstract available

  14. PISHKO AM, Bussel JB, Cines DB
    COVID-19 vaccination and immune thrombocytopenia.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01419.

  15. SIMPSON CR, Shi T, Vasileiou E, Katikireddi SV, et al
    First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01408.
    PubMed     Abstract available

  16. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    PubMed     Abstract available

  17. To curb COVID-19, global health must go local.
    Nat Med. 2021;27:929.

    May 2021
  18. MAY M
    After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
    Nat Med. 2021 May 31. pii: 10.1038/s41591-021-01393.

  19. AU L, Fendler A, Shepherd STC, Rzeniewicz K, et al
    Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Nat Med. 2021 May 26. pii: 10.1038/s41591-021-01387.
    PubMed     Abstract available

  20. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2021 May 21. pii: 10.1038/s41591-021-01363.

  21. SCHMIDT H, Weintraub R, Williams MA, Miller K, et al
    Equitable allocation of COVID-19 vaccines in the United States.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01379.
    PubMed     Abstract available

  22. WARD BJ, Gobeil P, Seguin A, Atkins J, et al
    Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01370.
    PubMed     Abstract available

  23. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2021 May 6. pii: 10.1038/s41591-021-01372.

  24. SINGH JA, Kochhar S, Wolff J
    Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 May 4. pii: 10.1038/s41591-021-01360.

  25. ANDREANO E, Rappuoli R
    SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
    Nat Med. 2021;27:759-761.

  26. OTU A, Agogo E, Ebenso B
    Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Nat Med. 2021;27:744-745.

    April 2021

  27. COVID-19 vaccine and blood clotting.
    Nat Med. 2021 Apr 29. pii: 10.1038/d41591-021-00025.

  28. DAL-RE R, Orenstein W, Caplan AL
    Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Nat Med. 2021 Apr 26. pii: 10.1038/s41591-021-01338.

  29. LI J, Hui A, Zhang X, Yang Y, et al
    Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Nat Med. 2021 Apr 22. pii: 10.1038/s41591-021-01330.
    PubMed     Abstract available

  30. ZARD M, Lau LS, Bowser DM, Fouad FM, et al
    Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations.
    Nat Med. 2021 Apr 19. pii: 10.1038/s41591-021-01328.

  31. GIORDANO G, Colaneri M, Di Filippo A, Blanchini F, et al
    Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Nat Med. 2021 Apr 16. pii: 10.1038/s41591-021-01334.
    PubMed     Abstract available

    The need for a new strategy for Ebola vaccination.
    Nat Med. 2021 Apr 5. pii: 10.1038/s41591-021-01313.

  33. EBINGER JE, Fert-Bober J, Printsev I, Wu M, et al
    Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Nat Med. 2021 Apr 1. pii: 10.1038/s41591-021-01325.
    PubMed     Abstract available

  34. EXCLER JL, Saville M, Berkley S, Kim JH, et al
    Vaccine development for emerging infectious diseases.
    Nat Med. 2021;27:591-600.
    PubMed     Abstract available

  35. CHEN RE, Zhang X, Case JB, Winkler ES, et al
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Nat Med. 2021;27:717-726.
    PubMed     Abstract available

  36. WIBMER CK, Ayres F, Hermanus T, Madzivhandila M, et al
    SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Nat Med. 2021;27:622-625.
    PubMed     Abstract available

  37. BURIONI R, Topol EJ
    Assessing the human immune response to SARS-CoV-2 variants.
    Nat Med. 2021;27:571-572.

  38. KINGANDA-LUSAMAKI E, Black A, Mukadi DB, Hadfield J, et al
    Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.
    Nat Med. 2021;27:710-716.
    PubMed     Abstract available

    March 2021
  39. CLARKE PM, Roope LSJ, Loewen PJ, Bonnefon JF, et al
    Public opinion on global rollout of COVID-19 vaccines.
    Nat Med. 2021 Mar 30. pii: 10.1038/s41591-021-01322.

  40. LEVINE-TIEFENBRUN M, Yelin I, Katz R, Herzel E, et al
    Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Nat Med. 2021 Mar 29. pii: 10.1038/s41591-021-01316.
    PubMed     Abstract available

  41. PLANAS D, Bruel T, Grzelak L, Guivel-Benhassine F, et al
    Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Nat Med. 2021 Mar 26. pii: 10.1038/s41591-021-01318.
    PubMed     Abstract available

    Vaccines reduce childhood mortality.
    Nat Med. 2021 Mar 18. pii: 10.1038/d41591-021-00014.

  43. SINGH JA, Kochhar S, Wolff J
    Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 Mar 16. pii: 10.1038/s41591-021-01299.

  44. EKSTROM AM, Berggren C, Tomson G, Gostin LO, et al
    The battle for COVID-19 vaccines highlights the need for a new global governance mechanism.
    Nat Med. 2021 Mar 11. pii: 10.1038/s41591-021-01288.

  45. MARHOLD K, Fell J
    Electronic vaccination certificates: avoiding a repeat of the contact-tracing 'format wars'.
    Nat Med. 2021 Mar 4. pii: 10.1038/s41591-021-01286.

  46. DURRHEIM DN, Andrus JK, Tabassum S, Bashour H, et al
    A dangerous measles future looms beyond the COVID-19 pandemic.
    Nat Med. 2021;27:360-361.

  47. AHMED I
    Dismantling the anti-vaxx industry.
    Nat Med. 2021;27:366.

    February 2021
  48. VAN DER VELDT AAM, Oosting SF, Dingemans AC, Fehrmann RSN, et al
    COVID-19 vaccination: the VOICE for patients with cancer.
    Nat Med. 2021 Feb 15. pii: 10.1038/s41591-021-01240.

  49. XIE X, Liu Y, Liu J, Zhang X, et al
    Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-021-01270.
    PubMed     Abstract available

  50. COVID-19 vaccines: acting on the evidence.
    Nat Med. 2021 Feb 4. pii: 10.1038/s41591-021-01261.

  51. STOWER H
    A functioning vaccine in mouse models of multiple sclerosis.
    Nat Med. 2021 Feb 1. pii: 10.1038/d41591-021-00006.

    January 2021
  52. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available

  53. KIM JH, Marks F, Clemens JD
    Looking beyond COVID-19 vaccine phase 3 trials.
    Nat Med. 2021 Jan 19. pii: 10.1038/s41591-021-01230.
    PubMed     Abstract available

  54. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2021 Jan 11. pii: 10.1038/s41591-020-01226.

    Women and children last? Shaking up exclusion criteria for vaccine trials.
    Nat Med. 2021;27:8.

  56. WAGAR LE, Salahudeen A, Constantz CM, Wendel BS, et al
    Modeling human adaptive immune responses with tonsil organoids.
    Nat Med. 2021;27:125-135.
    PubMed     Abstract available

  57. BURTON DR, Topol EJ
    Toward superhuman SARS-CoV-2 immunity?
    Nat Med. 2021;27:5-6.

    December 2020
  58. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01194.
    PubMed     Abstract available

  59. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01179.
    PubMed     Abstract available

  60. NACHBAGAUER R, Feser J, Naficy A, Bernstein DI, et al
    A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nat Med. 2020 Dec 7. pii: 10.1038/s41591-020-1118.
    PubMed     Abstract available

    Vaccines in the fast lane.
    Nat Med. 2020;26:1807.

    November 2020
  62. GALLAGHER ME, Sieben AJ, Nelson KN, Kraay ANM, et al
    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Nat Med. 2020 Nov 23. pii: 10.1038/s41591-020-01172.

    October 2020
  63. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2020 Oct 20. pii: 10.1038/s41591-020-1124.
    PubMed     Abstract available

  64. Scientists, keep an open line of communication with the public.
    Nat Med. 2020;26:1495.

    September 2020
  65. STOWER H
    Developing COVID-19 vaccines.
    Nat Med. 2020 Sep 10. pii: 10.1038/d41591-020-00029.

  66. TOSTANOSKI LH, Wegmann F, Martinot AJ, Loos C, et al
    Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
    Nat Med. 2020 Sep 3. pii: 10.1038/s41591-020-1070.
    PubMed     Abstract available

    August 2020
    Vaccines targeting SARS-CoV-2 tested in humans.
    Nat Med. 2020 Aug 24. pii: 10.1038/s41591-020-1048.

  68. STOWER H
    Seeds of hope in COVID-19 vaccine preliminary data.
    Nat Med. 2020;26:1170.

  69. PARK JK, Xiao Y, Ramuta MD, Rosas LA, et al
    Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Nat Med. 2020;26:1240-1246.
    PubMed     Abstract available

    July 2020
  70. ARNOLD C
    How computational immunology changed the face of COVID-19 vaccine development.
    Nat Med. 2020 Jul 15. pii: 10.1038/d41591-020-00027.

    June 2020
  71. STOWER H
    Vaccination combats antimicrobial resistance.
    Nat Med. 2020 Jun 11. pii: 10.1038/s41591-020-0957.

  72. 'T HOEN E
    Protect against market exclusivity in the fight against COVID-19.
    Nat Med. 2020;26:813.

    May 2020
  73. ARUNACHALAM PS, Charles TP, Joag V, Bollimpelli VS, et al
    T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.
    Nat Med. 2020 May 11. pii: 10.1038/s41591-020-0858.
    PubMed     Abstract available

    April 2020
  74. MOTHE B, Brander C
    Small steps forward for HIV vaccine development.
    Nat Med. 2020 Apr 2. pii: 10.1038/s41591-020-0837.

    March 2020
  75. COLBY DJ, Sarnecki M, Barouch DH, Tipsuk S, et al
    Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
    Nat Med. 2020 Mar 23. pii: 10.1038/s41591-020-0774.
    PubMed     Abstract available

  76. TADROS AR, Romanyuk A, Miller IC, Santiago A, et al
    STAR particles for enhanced topical drug and vaccine delivery.
    Nat Med. 2020;26:341-347.
    PubMed     Abstract available

    February 2020
  77. KOTLIAROV Y, Sparks R, Martins AJ, Mule MP, et al
    Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus.
    Nat Med. 2020 Feb 24. pii: 10.1038/s41591-020-0769.
    PubMed     Abstract available

  78. LANGENBERG MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, et al
    A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.
    Nat Med. 2020 Feb 17. pii: 10.1038/s41591-020-0759.
    PubMed     Abstract available

  79. DUSSUPT V, Sankhala RS, Gromowski GD, Donofrio G, et al
    Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Nat Med. 2020 Feb 3. pii: 10.1038/s41591-019-0746.
    PubMed     Abstract available

  80. DORE GJ, Martinello M, Alavi M, Grebely J, et al
    Global elimination of hepatitis C virus by 2030: why not?
    Nat Med. 2020;26:157-160.

    January 2020
  81. STOWER H
    A conjugate vaccine for typhoid.
    Nat Med. 2020;26:21.

    October 2019
  82. EHRHARDT SA, Zehner M, Krahling V, Cohen-Dvashi H, et al
    Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0602.
    PubMed     Abstract available

  83. STOWER H
    Supporting HPV vaccination.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0618.

    A glimpse into immune responses evolving against Ebola virus.
    Nat Med. 2019;25:1470-1471.

    August 2019
  85. CHAN KR, Gan ES, Chan CYY, Liang C, et al
    Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection.
    Nat Med. 2019;25:1218-1224.
    PubMed     Abstract available

    Rethinking herd immunity.
    Nat Med. 2019;25:1178-1180.

    July 2019

  87. Time to vaccinate against hesitancy.
    Nat Med. 2019 Jul 3. pii: 10.1038/s41591-019-0524.

    May 2019

  88. HIV vaccines go to trial.
    Nat Med. 2019;25:703.

    April 2019
  89. HAMMERICH L, Marron TU, Upadhyay R, Svensson-Arvelund J, et al
    Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
    Nat Med. 2019 Apr 8. pii: 10.1038/s41591-019-0410.
    PubMed     Abstract available

    January 2019
  90. YAMAYOSHI S, Kawaoka Y
    Current and future influenza vaccines.
    Nat Med. 2019 Jan 28. pii: 10.1038/s41591-018-0340.
    PubMed     Abstract available

  91. DIJKMAN K, Sombroek CC, Vervenne RAW, Hofman SO, et al
    Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0319.
    PubMed     Abstract available

    November 2018
    A vaccine for tuberculosis.
    Nat Med. 2018;24:1637.

    September 2018
  93. ACKERMAN ME, Das J, Pittala S, Broge T, et al
    Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
    Nat Med. 2018 Sep 3. pii: 10.1038/s41591-018-0161.
    PubMed     Abstract available

    August 2018
  94. OKOYE AA, Hansen SG, Vaidya M, Fukazawa Y, et al
    Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
    Nat Med. 2018 Aug 6. pii: 10.1038/s41591-018-0130.
    PubMed     Abstract available

    June 2018
  95. XU K, Acharya P, Kong R, Cheng C, et al
    Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
    Nat Med. 2018;24:857-867.
    PubMed     Abstract available

    May 2018
  96. VACCARI M, Fourati S, Gordon SN, Brown DR, et al
    HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition.
    Nat Med. 2018 May 21. pii: 10.1038/s41591-018-0025.
    PubMed     Abstract available

    April 2018

  97. A checkup for the flu vaccine.
    Nat Med. 2018;24:375.

  98. DRAPER SJ, Higgins MK
    A new site of attack for a malaria vaccine.
    Nat Med. 2018;24:382-383.

    March 2018
    Going live: How microRNAs might bring living vaccines back into the fold.
    Nat Med. 2018;24:248-250.

    February 2018
    A shot at contraception: In India, a nonagenarian renews testing of a birth control vaccine.
    Nat Med. 2018;24:118-120.

  101. CARPENTER SM, Behar SM
    A new vaccine for tuberculosis in rhesus macaques.
    Nat Med. 2018;24:124-126.

    January 2018
  102. HANSEN SG, Zak DE, Xu G, Ford JC, et al
    Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
    Nat Med. 2018 Jan 15. pii: nm.4473. doi: 10.1038/nm.4473.
    PubMed     Abstract available

  103. JANSEN KU, Knirsch C, Anderson AS
    The role of vaccines in preventing bacterial antimicrobial resistance.
    Nat Med. 2018;24:10-19.
    PubMed     Abstract available

    November 2017
  104. ARNOLD C
    Stalking new vaccines: Methods that target the stems of viral proteins could put universal vaccines within reach.
    Nat Med. 2017;23:1248-1250.

    July 2016
  105. MODJARRAD K, Moorthy VS, Ben Embarek P, Van Kerkhove M, et al
    A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.
    Nat Med. 2016;22:701-5.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.